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Abstract.
Objective: To evaluate the clinicopathologic and functional outcomes of a modified Vescica ileale Padovana (VIP) neobladder
technique.
Methods: Data for 160 patients at a single institution who underwent radical cystectomy and orthotopic VIP neobladder creation
between 1998 and 2013 were analyzed. Modified VIP technique involved longitudinal opening of the small bowel close to the
anterior mesenteric border instead of along the true anti-mesentery. This allowed for creation of a dependent neourethral funnel
and a large serosal surface for ureteral anastomosis, distant from any suture lines.
Results: Mean age for the entire cohort was 59.5, with 9% female and 64% with muscle invasive disease prior to cystectomy.
Within 30 days of surgery, 16 patients (10%) developed a Clavien grade 3-4 complication and there were no deaths. Ninety-six
percent reported minor or no daytime urinary leakage at 12 months, and 70% reported minor or no nighttime urinary leakage.
Two- and five-year overall survival rates were 84.2% and 72.6%, respectively. Seven patients developed a ureteral stricture (4%),
three (2%) had bladder neck contractures, two (1%) experienced urethral recurrence, and there were no vesicovaginal fistulas.
Conclusions: This modified VIP neobladder technique achieves favorable functional, survival, and recurrence outcomes similar
to other published orthotopic continent diversions. Its near spheroidal shape lowers internal pressure, allowing for improved
continence at physiologic filling capacity, and its offset bowel opening helps prevent unnecessary stretch to the native urethra,
even in large individuals. The widened uretero-enteric anastomosis site distant from bowel suture lines contributes to decreased
stricture rates and its placement on the dome of the neobladder facilitates endoscopic access should strictures occur. Finally,
lack of posterior overlapping suture lines also mitigates the risk of fistulae formation in females should anterior vaginal wall
excision or entry be unavoidable.
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INTRODUCTION
Radical cystectomy remains the gold standard for
management of muscle-invasive bladder cancer [1, 2].
Estimates using data from the Surveillance, Epidemi-
ology, and End Results (SEER) database predict that
approximately 18,600 new muscle-invasive bladder
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cancer cases will be diagnosed in 2014. Analysis of
this SEER data reveals that 42% of these patients with
muscle-invasive disease ultimately undergo cystec-
tomy [3], necessitating the surgical diversion of urine
in the form of an incontinent ileal conduit, a continent
orthotopic pouch that empties via urethra, or a catheter-
izable non-orthotopic cutaneous stoma [4]. Orthotopic
neobladders allow voiding through the native ure-
thra and can potentially eliminate the need for stoma
appliances or catheters without compromising cancer
control [5]. Neobladders created from ileum have been
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found to be more compliant than those created with
large bowel [6], and by detubularizing and refolding
into a spherical shape, low pressure filling at physio-
logic capacity can best be achieved [6]. Specifically,
spherical configurations maximize volume for any
given surface area, thus decreasing the length of bowel
needed for harvest and minimizing the opportunity for
electrolyte exchange across the neobladder wall [7].
The specific folding method used varies greatly among
institutions and little evidence exists that definitively
favors one technique versus another.
Two techniques routinely used at our institution for
neobladder creation are the Studer and the vescica
ileale Padovana (VIP) techniques. A distinction of
the VIP technique is its complete use of bowel seg-
ment in the spherical component of the neobladder [8]
whereas the Studer neobladder involves the creation
of an afferent limb that does not contribute to bladder
volume [9]. There are many published studies avail-
able that report functional and oncologic outcomes for
the Studer neobladder [10–13], but fewer large stud-
ies exist that offer data on such outcomes specifically
following VIP neobladder creation [8, 14].
Modified creation of the Vescica ileale Padovana
(VIP) neobladder has been performed at our insti-
tution over a 15-year period. We sought to evaluate
the clinicopathologic and functional outcomes of this
technique.
METHODS
Patients
After obtaining Institutional Review Board approval
for the conduct of this unfunded study, a retrospective
review of a single-institution bladder cancer database
was performed to identify patients who underwent
radical cystectomy with VIP neobladder orthotopic
replacement between 1998 and 2013. Only adults (>17
years) were included in the study and all patients had
primary urothelial cancer of the bladder.
Outcomes and variables
Functional and clinicopathologic outcomes were the
primary outcomes of interest in this study. Variables
collected for each patient included age, sex, body
mass index (BMI), TURBT and cystectomy stage, pre-
and post-operative creatinine, neoadjuvant and adju-
vant chemotherapy, case length, estimated blood loss
(EBL), length of stay (LOS) in the hospital, 30-day
and long term complications including vesicovaginal
fistula, presence of hydronephrosis at three weeks
and twelve months, and functional outcomes. Func-
tional outcomes included the need to catheterize at
twelve months, daytime control at twelve months,
and nighttime control at twelve months. Continence
and need to catheterize was assessed by physician
interview. Other follow-up variables included subse-
quent development of a ureteral stricture, bladder neck
contracture, and urethral recurrence. Overall survival
status was assessed using our departmental database
and the Social Security Death Index. A Kaplan-Meier
overall survival curve was generated using Stata 12.1
(Stata Corp, College Station, TX).
Case length was defined as the time from skin
opening to skin closure. 30-day complications were
classified using the modified Clavien-Dindo sys-
tem [15]. Patients receiving perioperative blood
transfusion were classified as having a Clavien grade
2 complication. Only the highest-grade complica-
tions were reported. Hydronephrosis was assessed
by intravenous pyelogram in the immediate post-
operative period, and long-term surveillance imaging
included renal ultrasound or cross-sectional imaging
with CT/MRI. Daytime control was defined by patient
report of normal, minor, or major leakage on the major-
ity of days each week. Nighttime control was defined
by patient report as no leakage, occasional (1-2 times
per week) low volume leakage, occasional high vol-
ume leakage, frequent (>2 times per week) low volume
leakage, or frequent high volume leakage. Variables
were assessed for completeness. BMI was missing for
33% of patients (n = 53/160), preoperative creatinine
was missing for 13% (n = 20/160), case time was miss-
ing for 33% (n = 53/160), and EBL was missing for
12% (n = 19/160). The majority of patients with miss-
ing data were operated upon prior to 2003.
Surgical description
VIP neobladder construction was based on its initial
report [8], with minor modifications by the surgeon.
Briefly, a 40–50 cm distal ileal segment approximately
15–20 cm from the ileocecal valve is folded into a
sideways-“U” configuration. The small bowel is then
opened longitudinally, close to the mesenteric border
instead of along the true anti-mesentery. The distal
segment of bowel, using the minimum length nec-
essary as determined by patient anatomy (∼3-4 cm)
is then fashioned into a funnel to form the bladder
neck/neourethra. The proximal segment is folded into
a spiral configuration with adjacent bowel sutured
together in order to approximate the new posterior
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Table 1
VIP neobladder patient characteristics
Variable n (%) = 160
Age, mean (SD) 59.5 (10.4)
Sex
Female 14 (9)
Male 146 (91)
BMI, mean (SD) 28.2 (4.9)
TURBT stage
≤T1 58 (36)
≥T2 102 (64)
Neoadjuvant chemotherapy 20 (13)
Preoperative creatinine, mean (SD) 1.11 (0.3)
Postoperative creatinine, mean (SD) 1.10 (0.3)
Pathologic stage
pT0, pTis, pTa 55 (34)
pT1 21 (13)
pT2 36 (23)
pT3 38 (24)
pT4 10 (6)
Lymph nodes positive 36 (23)
Adjuvant chemotherapy 50 (31)
Length of case, mean (SD) 239 (38) min.
EBL, mean (SD) 564 (435) mL
LOS, mean (SD) 7.3 (2.8) days
∗BMI missing for 53/160, pre-operative creatinine missing 20/160,
case time missing for 53/160, EBL missing for 19/160.
wall. The pouch is folded onto itself in a cephalad
to caudad fashion. Using a non-tunneled anastomo-
sis, both ureters are reimplanted on their respective
sides onto the superior portion of the neobladder.
The pouch is tested intraoperatively, with an aver-
age initial capacity of 200–400 mL. Ureteral stents
are brought out through the urethra alongside the
indwelling catheter. Among female patients under-
going cystectomy with VIP neobladder creation, the
anterior vaginal wall was spared. In those patients with
entry into the anterior vaginal wall, primary repair was
performed without flap-interposition prior to neoblad-
der creation. All patients received 2 grams of Cefoxitin
for 24 hours as antibiotic prophylaxis. Additionally,
patients received either 40 mg of enoxaparin daily or
5000 units of heparin three times daily as thromboem-
bolism prophylaxis during hospitalization.
RESULTS
One hundred and sixty patients were identified as
undergoing VIP neobladder creation during the study
period. Patient characteristics are shown in Table 1.
The majority of patients underwent radical cystectomy
for muscle invasive bladder cancer (64%). Forty-seven
percent of patients had ≤pT1 disease on cystectomy
pathology, and 30% of patients were pT3-4.
Table 2
Post-operative complications in patients undergoing VIP neobladder
replacement
Complication n (%) = 160
30 day Clavien grade
Clavien 1 25 (16%)
Clavien 2 30 (19%)
Clavien 3 6 (4%)
Clavien 4 10 (6%)
Clavien 5 0 (0%)
Vesicovaginal fistula 0 (0%)
Ureteral stricture 7 (4%)
Urethral stricture 1 (1%)
Bladder neck contracture 3 (2%)
With regard to early and late complications
(Table 2), 16 patients (10%) developed a Clavien
grade 3-4 complication within 30 days of surgery,
and no patients died within 30 days of surgery
(Clavien grade 5). Of the 13 women undergoing mod-
ified VIP replacement, all had attempted sparing of
the anterior vaginal wall and none were clinically T3
or higher at the time of surgery. Two patients had
small inadvertent vaginotomies that were closed pri-
marily. There were no vesicovaginal fistulas. Seven
patients (4%) developed ureteral stricture, four of
which occurred within one year of surgery. All stric-
tures were managed successfully: five with ureteral
reimplantation, one with an ileal ureter, and one with
temporary stenting. Three patients (2%) developed a
bladder neck contracture, two of which occurred within
one year of surgery. Two contractures were managed
by incision, one was managed with sequential dilation,
and only one patient required intermittent catheteriza-
tion following contracture. One patient developed a
late urethral stricture (1%), which was managed with
conversion to ileal conduit.
Median follow-up of patients was 73 months. Two
patients (1%) experienced urethral recurrence. Over-
all survival is shown in Fig. 2, with median survival
not reached. Two-year overall survival was 84.2% and
five-year overall survival was 72.6%. Fifteen patients
died within one year of surgery, ten of which had pro-
gression of disease and five were disease free at last
follow-up.
Functional outcomes are shown in Table 3,
representing only those patients with twelve-month
follow-up (n = 107). Incidence of mild hydronephrosis
decreased dramatically from the three-week to twelve-
month appointments and no patients had moderate or
severe hydronephrosis at either point in time. Seven
patients (7%) were catheterization dependent at 12
months due to urinary retention, and an additional nine
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Fig. 1. Modified VIP neobladder construction. (A) A 40–50 cm distal ileal segment is chosen approximately 15–20 cm from the ileocecal valve
and (B) is folded into a sideways “U” configuration. The small bowel is opened longitudinally, close to the mesenteric border instead of along
the true anti-mesentery. (C) The distal segment of bowel is tubularized into the neourethra and (D) the proximal segment is folded into a spiral
configuration with adjacent bowel sutured together to approximate the new posterior wall. (E) The pouch is folded onto itself in a cephalad to
caudad fashion and both ureters are reimplanted anteriorly on their respective sides.
Table 3
Functional outcomes at twelve-month follow-up appointment
(n = 107)
Mild hydronephrosis at 3 weeks 35 (33)
Mild hydronephrosis at 12 months 12 (11)
Catheterize 1/day at 12 months 16 (15)
Catheterization dependent at 12 months 7 (7)
Daytime control at 12 months
No leakage 82 (76)
Minor leakage 21 (20)
Major leakage 4 (4)
Nighttime control at 12 months
No leak 28 (26)
Occasional low leakage 47 (44)
Occasional high leakage 0
Frequent low leakage 18 (17)
Frequent high leakage 14 (13)
patients opted to catheterize daily in addition to spon-
taneous voiding in order to ensure complete emptying.
DISCUSSION
The technique for VIP neobladder creation was
first described in 1990, with its authors advocating
orthotopic bladder replacement following cystectomy
as “the ideal solution to enhance the quality of the
Fig. 2. Overall survival for VIP neobladder patients.
patient’s life.” Their new surgical technique promised
improved rates in both daytime and nighttime conti-
nence [8]. In performing this study we were able to
investigate the validity of this claim as well as explore
other clinicopathologic outcomes resulting from this
particular method of bladder substitution.
In our modified technique for the neobladder there
are several distinct advantages. The near pure spherical
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configuration maximizes the ratio of bladder volume
to amount of bowel utilized [16]. Offset opening of the
bowel wall results in a wider, well-vascularized bowel
segment to use for ureteral reimplantation. This allows
for a minimally mobilized ureter and reimplantation
distant from any suture lines, which contributes to the
very low ureteral stricture rate. This placement also
ensures that when ureteral strictures do occur, they
are easily accessible surgically. Stricture rates in the
literature are reported to be as low as 2.7% follow-
ing refluxing anastomosis, and we found our own rates
to be comparable [12, 17]. Offset opening also facili-
tates ease in reaching the native urethra (even in obese
individuals) when creating the neourethra, a depen-
dent funnel that promotes better bladder emptying.
And finally, this modified technique results in interven-
ing mesentery that avoids posterior overlapping suture
lines. This mitigates risk of fistulae formation poten-
tially caused by ongoing urinary drainage into areas of
injury [11, 18–20] should tumor anatomy necessitate
removal of the anterior vaginal wall or if inadvertent
entry is unavoidable. In our own experience, with two
unplanned vaginotomies, neither resulted in vesicov-
aginal fistula.
Our rate of reported postoperative complications,
while significant, was at the low end of ranges reported
previously. Given the extent of disease and scope of this
procedure, expected morbidity following radical cys-
tectomy is high, ranging from 20 to 57% during the
first 30 days postoperatively as reported in a review by
Richards et al. [21] and rising to 64% of patients within
the first 90 days as reported by Shabsigh et al. [22]. In
the previously discussed studies, as well as within our
own cohort, the predominant percentage of complica-
tions was minor in nature. Fortunately, despite these
high complication rates mortality remains relatively
low, with 1.5% deaths in the first 30 days as reported
by Shabsigh et al. [22] and no perioperative deaths
reported in our own series.
When comparing on the basis of quality of life,
available literature does not definitively support the
implementation of one type of reconstruction over
another [23, 24]. With a funneled bladder outlet,
there is some reported concern for kinking requiring
catheterization to void [12]. However, the anatomic
placement of the neobladder reservoir helps to avoid
this concern for retention, with only seven patients
requiring intermittent catheterization to void at one
year. This is similar to that seen in other large
cohorts, for example Studer et al. report 4.6% use of
indwelling catheter or intermittent catheterization in
their cohort [12]. Continence varies slightly between
published cohorts based on the definition used. How-
ever, despite this, our rates compare favorably to those
seen previously [10, 14, 16] with daytime continence
(no leakage or minor leakage) at 96% and nighttime
continence (no leak or occasional low leakage) of 70%.
Hautmann et al. report ranges of 88–95% daytime
and 66–93% nighttime in their review of the literature
[16]. Studer et al. too found with their technique that
12 months after surgery, 92% of neobladder patients
considered themselves continent (completely dry or
minimal loss of a few drops of urine, 1-2 times per
month) during the day and 79% reported continence
at night [12, 25]. Although there are a number of fac-
tors including patient age as well as attempted nerve
sparing and native sphincter preservation [16] that con-
tribute to continence, the ability to achieve low pressure
filling at physiologic capacity is a major contributor to
both daytime and nighttime continence. This highlights
the importance of the nearly spheroidal configuration
of this neobladder technique.
Results of this study reveal favorable oncologic
outcomes as compared to other published orthotopic
diversions. Our five-year overall survival was 72.6%,
as compared to the series published by Stein et al. that
reported 66% 5-year overall survival in their cohort
of 1,054 patients undergoing cystectomy [1]. Maders-
bacher et al. too reported a 5-year overall survival of
59% in 507 patients undergoing cystectomy for node
negative, metastasis negative transitional cell carci-
noma [2, 6]. Because neobladder creation necessitates
sparing the urethra, it carries with it an inherent risk
of urethral recurrence not universally present in other
forms of continent diversion where urethrectomy is
possible. Despite mitigating this risk with intraopera-
tive urethral frozen section analysis, a small percentage
of recurrences are expected. Our personal experience
yielded two urethral recurrences (1%), which corre-
lates well with a meta-analysis by Gakis et al. that
reports urethral recurrence rates with orthotopic diver-
sion of 1.1–2.5% [6]. These favorable results likely
relate to patient selection, whereby patients chosen for
neobladder creation are often lower clinical stage with
less muscle invasive disease. This is evidenced by the
fact that nearly half of our patients had ≤ pT1 disease
on cystectomy pathology and only ten patients were
pT4.
We recognize that there are limitations in this
study. Because the study is purely descriptive, with-
out comparison or randomization, there is potential
for bias whereby physician selection of patients with
a potentially higher preoperative functional status and
more favorable tumor features might bias the study
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results. Indeed our cohort has a predominance of
younger patients with low stage disease, however this
reflects the reality of patient selection for orthotopic
bladder replacement – an option typically reserved by
for patients meeting strict criteria that would indicate
success. A lack of validated pre- and postoperative
quality of life data makes comparison to other studies
more challenging. Previously, generic questionnaires
set strict standards for a definition of ‘continence’,
particularly nighttime continence, that is potentially
unreasonable to expect in the post-cystectomy setting.
Although disease specific quality of life questionnaires
have since been validated [27, 28] to address con-
cerns that are more specific to this population such
as need for catheterization, difficulties with stoma care
or stoma appliances, and the distinction between day-
time and nighttime continence, [23] many institutions
(including ours) have only recently begun to incorpo-
rate these into practice. Perhaps the most challenging
limitation is the retrospective nature of this study and
its incomplete data set. Nevertheless, we believe that
our cohort represents one of the largest experiences in
the literature to assess functional, complication, and
clinicopathologic outcomes in this unique population.
CONCLUSION
Modified VIP neobladder technique achieves favor-
able functional, survival, and recurrence outcomes
similar to other published orthotopic continent diver-
sions. Its near spheroidal shape optimizes the bowel
surface area to volume ratio, lowering internal pressure
and allowing for improved continence at physiologic
filling capacity. Its offset bowel opening helps pre-
vent unnecessary stretch to the native urethra, even in
large individuals. The widened uretero-enteric anasto-
mosis site distant from bowel suture lines contributes to
decreased stricture rates and its placement on the dome
of the neobladder facilitates endoscopic access should
strictures occur. Finally, lack of posterior overlapping
suture lines also mitigates the risk of fistulae forma-
tion in females should anterior vaginal wall excision
or entry be unavoidable.
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